H. Gauani

Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension.

M. Corboz, Zhili Li, D. Cipolla, 2021, European journal of pharmacology.

Assessment of Inhaled Treprostinil Palmitil, Inhaled and Intravenous Treprostinil and Oral Selexipag in a Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension

M. Corboz, Zhili Li, V. Malinin, 2022, Journal of Pharmacology and Experimental Therapeutics.

Treprostinil palmitil, an inhaled long-acting pulmonary vasodilator, does not show tachyphylaxis with daily dosing in rats.

M. Corboz, Zhili Li, D. Cipolla, 2020, Pulmonary pharmacology & therapeutics.

Inhaled hexadecyl-treprostinil provides pulmonary vasodilator activity at significantly lower plasma concentrations than infused treprostinil.

M. Corboz, Zhili Li, D. Salvail, 2018, Pulmonary pharmacology & therapeutics.

Evaluation and Selection of the Inhaler Device for Treprostinil Palmitil Inhalation Powder

Zhili Li, V. Malinin, E. Sullivan, 2022, Frontiers in Drug Delivery.

Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension

M. Corboz, Zhili Li, D. Cipolla, 2021, International journal of molecular sciences.

Effect of Inhalation Profile on Delivery of Treprostinil Palmitil Inhalation Powder

Zhili Li, V. Malinin, E. Sullivan, 2023, Pharmaceutics.

Preclinical Investigation of a Lipoglycopeptide Dry Powder Inhalation Therapy for the Treatment of Pulmonary MRSA Infection

V. Malinin, Amruta A. Sabnis, A. Plaunt, 2023, Pharmaceutics.